Data demonstrates that NewCardio's platform technology delivers new levels of analysis of heart's electrical activity
SANTA CLARA, Calif., May 18 /PRNewswire-FirstCall/ -- NewCardio, Inc., a cardiac diagnostic and services company, today announced that members of the Company's medical and technology teams presented two abstracts and discussed new clinical data from analytical and clinical applications of its proprietary platform technology at The Heart Rhythm Society (HRS) 30th Annual Scientific Sessions on May 13-16, 2009 in Boston, MA.
NewCardio introduced the NewCardio platform, QTinno(TM) and Visual3Dx(TM), at Heart Rhythm 2009 30th Annual Scientific Sessions. The Company believes that its QTinno(TM), software-based, analytical technology is the industry's first solution for the reliable automated analysis of ECGs used to determine cardiac toxicity during drug development. Visual3Dx(TM) will generate 3D information from the heart using standard 12-lead ECG data. It is expected to provide clinicians additional information on the extent and localization of acute ischemic insult to the heart to improve the speed and accuracy of diagnosis of Acute Coronary Syndrome.
HRS is the international leader in science, education and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders. Its mission is to improve the care of patients by promoting research, education and optimal health care policies and standards. The Annual Scientific Sessions attract more than 9,000 professionals representing the allied specialties of cardiac pacing and cardiac electrophysiology. More information is available at http://www.hrsonline.org/Sessions/ on the Internet.
The two abstracts presented were:
"Vectorcardiographic Evidence of Cardiac Memory During Continuous Ventricular Pacing," authored by Drs. Alexei Shvilkin, Mark Josephson and Peter Zimetbaum, all of the Department of Medicine/Division of Cardiology at the Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, as well as Drs. Bosko Bojovic (NewCardio's co-founder and senior consultant), Branislav Vajdic (NewCardio's Chief Executive Officer), and Ihor Gussak (NewCardio's Chief Medical Officer). This study presents data demonstrating the ability to identify cardiac memory (post-pacing T wave abnormality) during continuous ventricular pacing using the Company's 3-dimensional ECG interpretation tools. Previously, this phenomenon was only described in the setting of a return to normal ventricular activation. This observation advances our understanding of wide complex rhythms physiology and serves as a basis for improving ECG diagnosis in the setting of abnormal ventricular activation (left bundle branch block (LBBB) and ventricular pacing).
"Vectorcardiographic Discrimination Between Acute and Chronic Left Bundle Branch Block," authored by Drs. Shvilkin, Josephson and Zimetbaum from the Beth Israel Deaconess Medical Center/Harvard Medical School, as well as Drs. Bojovic, Vajdic and Gussak. The study demonstrates that by using NewCardio's platform technology, it is possible to distinguish new onset left bundle branch block (LBBB) from a chronic one. This constitutes a significant diagnostic advance in a setting of acute coronary syndrome (ACS). Currently, new or presumed new onset LBBB is a Class I indication for primary percutaneous coronary intervention or fibrinolytic therapy in patients presenting with symptoms consistent with ACS. Up until now there have been no diagnostic criteria to distinguish new onset from chronic LBBB and if no prior ECGs were available it had to be presumed "new." NewCardio technology allows the reader to determine the duration of LBBB without previous ECG tracings. This finding can potentially reduce the number of unnecessary coronary interventions.
Branislav Vajdic, PhD, NewCardio's Chief Executive Officer, commented, "These two abstracts clearly demonstrate the power of NewCardio's platform technology in difficult clinical settings. This solution enables doctors to obtain much more clinically relevant information than previous technologies allowed, setting the stage for clinical advances which have the potential to save lives by more rapidly and accurately diagnosing cardiac events. We are excited to have had the opportunity to discuss these findings at the Heart Rhythm Society conference, the premier gathering for the electrophysiology community."
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. NewCardio's three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. For more information, visit www.newcardio.com.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2008 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.
To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0
CONTACT: Jeff Stanlis, Partner and Vice President of Communications of
Hayden IR, +1-602-476-1821, jeff@hayednir.com, for NewCardio, Inc.
Web site: http://www.newcardio.com/
